Priyanka singh (taj pharma) firstwordpharma com node

Search

[New Report] Real World Data Capabilities: Benchmarking Pharma Companies - Stay ahead in the data race and download now

Home Partner Showcase Register Free Trial Contact Us Advertise My News My CompanyWatch My ConditionWatch My MedicalMeetingWatch My ProductWatch My RegulatoryWatch My Saved Searches All News Trending Business Company Condition Medical Meeting Product Regulatory Therapeutic Category All Insight, Analysis and Views ViewPoints Lists Physician Views KOL Views Spotlight On Friday Five Analyst Notes Other StoryWatch Deals - Alliances Financing W eb page converted to PDF w ith the PDFmyURL PDF creation API!

Login • Subscribe Saturday, April 01, 2017 Search

FDA AdCom Tracker Focus on Gene Therapy Focus on Orphan Drugs Market Access Issues Pharma Reacts to Brexit Where Health Meets Tech Emerging Markets Focus on Biosimilars Latest Earnings Reports Product Approvals Channel Mobile Twitter RSS Podcasts Videos

- (The Economic Times via NewsPoints Desk)

Novartis AG: Lupin, Cipla, other top drugmakers in fray for Novartis’ brands - (The Economic Times via NewsPoints Desk)

(Ref: The Economic Times) March 30th, 2017 Tags: NewsPoints TOBI Cadila Healthcare Cipla Lupin Novartis Sanofi Sun Pharmaceutical Cystic Fibrosis Pulmonary/Respiratory Medicine Corporate Affairs Mergers & Acquisitions

According to people familiar with the matter, Lupin, Cipla, Zydus Cadila and Sun Pharmaceutical are seeking to acquire the respiratory drugs portfolio that Novartis is trying W eb page converted to PDF w ith the PDFmyURL PDF creation API!

0

to divest, reported The Economic Times.

1 Like

0

Recent Reports

The sources suggested that the portfolio of brands on offer,

The Future of Medical Affairs (Ref. FirstWord

including the TOBI Podhaler, which is estimated to have

Dossier)

$300 million in annual global revenue, could fetch as much as $500 million in a sale.

Biosimilars: European Payer Perspectives (2017) Share

Tweet

The winning suitor may have to agree to source the products from Novartis for a specified period of time before they can sub-contract manufacturing to a third party, the sources noted.

(Ref. FirstWord Dossier) KAM Metrics: Measuring Success (Ref. FirstWord Dossier)

Email Print

The interest from the Indian companies is preliminary and no firm offers have been made, the people cautioned, while a Novartis spokesperson declined to comment on the speculation.

Insight, Analysis and Views KOL Views: Ocrevus has finally arrived – how will it change the way MS is treated and what competing drugs are in the cross-hairs?

ViewPoints: GlaxoSmithKline, Innoviva, Teva and

Meanwhile, the news source said Lupin, which has been looking for acquisition opportunities in the respiratory segment, is also reported to be in talks with Sanofi to acquire respiratory drugs from its generics division Zentiva.

Hikma toast to Mylan’s misfortune with Advair generic Physician Views Poll Results: Broad label should mean broad and rapid adoption for Tesaro's Zejula

FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

All Contents Copyright © 2017 Doctor's Guide Publishing Limited. All Rights Reserved.

Share this Article

Terms of Use | Privacy Policy

1 Like Share

Google

Facebook

Pharma | Contact FirstWord Pharma | FirstWord Reports Advertise with FirstWord Pharma | Industry Partner Showcase

To read more NewsPoints articles, click here.

0

About FirstWord Pharma | Refer a Colleague | Upgrade Your FirstWord

LinkedIn

Tw eet

Email

Print

W eb page converted to PDF w ith the PDFmyURL PDF creation API!

Tw eeter

Related News Cadila Healthcare close to buying Claris Lifesciences' generic sterile injectables unit for about $534 million: report India's Drugmakers Step Up US Investment Sun Pharma acquires certain Japanese brands from Novartis in $293-million deal Indian pharma's struggle to tighten standards paves way for M&A deals Sun Pharma to buy Japanâ&#x20AC;&#x2122;s branded portfolio of Novartis (VIDEO)

Reference Articles Novartis AG: Lupin, Cipla, other top drugmakers in fray for Novartisâ&#x20AC;&#x2122; brands - (The Economic Times)

W eb page converted to PDF w ith the PDFmyURL PDF creation API!